The US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on May 18, 2026, to VER-01, a cannabis-based pain medication developed by Munich-based pharmaceutical company Vertanical, for the treatment of chronic back pain. It is the first Breakthrough Designation ever awarded for a cannabis-based pain medication and only the second FDA recognition for a cannabis-derived drug following Epidiolex in 2018. According to the company, the European market launch under the brand name Exilby is imminent, expected within weeks.
📑 Inhaltsverzeichnis
VER-01 is a standardized full-spectrum extract from a proprietary Cannabis sativa strain designated internally as DKJ127 L. In addition to classical cannabinoids, the preparation contains cannabigerol, beta-caryophyllene, and alpha-bisabolol, and is administered as an oral solution. This fundamentally distinguishes it from prescription-eligible cannabis flowers, which have seen strong demand in German pharmacies since the enactment of the Cannabis Act, as well as from the isolated CBD active ingredient in Epidiolex. The Munich development was first presented in a background report on VER-01 on hanf-magazin.com in 2025. At that time, FDA recognition was still pending.
What the Breakthrough Designation Triggers Regulatorily
The FDA’s Breakthrough Therapy Designation is not an expedited approval process but rather an accelerated consultation status. The agency commits itself to intensive guidance during development and expedited review once final study data are available. The prerequisite is that the active ingredient is intended for a serious illness and preliminary clinical data demonstrate substantial improvement over existing therapies. Vertanical has cleared this hurdle with the Phase 3 data published to date.
For the German pharmaceutical company, the designation is strategically valuable in two ways. First, it grants privileged FDA access for the ongoing US study, whose data readout is expected in 2027. A regulatory submission is planned for 2028. Second, it provides an internationally recognized seal of quality designed to secure the European market launch. The Breakthrough Designation is not a frequently granted status. In comparison to Epidiolex from Jazz Pharmaceuticals, which generates approximately $100 million in annual sales, VER-01 targets a significantly larger indication field: chronic back pain affects roughly 500 million people worldwide.
The Evidence Base Behind the Active Ingredient
The designation is based on two Phase 3 studies. The first, published in Nature Medicine in September 2025, encompassed 820 patients and compared VER-01 in a placebo-controlled design. The primary endpoint was achieved, effects proved sustained, and there were significant improvements in sleep quality and physical function. The second study, called ELEVATE, enrolled 384 patients at centers in Germany, Czech Republic, Poland, and Spain. It directly compared VER-01 to an opioid comparator and demonstrated superior pain reduction with better gastrointestinal tolerability. No evidence of dependence or withdrawal symptoms was found.
This point is regulatorily central. The opioid comparison positions VER-01 as a direct substitution candidate in an indication where one in five acute patients in the United States receives an opioid prescription today. In Germany, too, chronic back pain is one of the most common indications for long-term opioid therapy. The study design addresses a health policy-sensitive gap that has also been illuminated in recent years through observational studies, such as the NIH analysis of opioid poisonings in legalized US states or the current data on cannabinoids in pain management and the assessment of medicinal cannabis for back pain.
European Launch Under the Brand Name Exilby
Vertanical has been preparing for the European market entry for years. CEO Clemens Fischer, who simultaneously leads the Munich-based FUTRUE Group, has placed development costs at over $250 million. The market entry model envisions German approval as the first market, followed by an EU-wide mutual recognition procedure. This would make VER-01, or Exilby, the first prescription cannabis pain medication with standard pharmaceutical approval in Germany, clearly distinguished from flower prescriptions under the Medical Cannabis Act.
This distinction is strategically decisive. While the federal government plans through the Medical Cannabis Act amendment to restrict mail-order sales of cannabis flowers and tie initial prescriptions to personal doctor-patient contact, VER-01 functions as a regular finished pharmaceutical and is therefore not directly affected by these restrictions. For Vertanical, this opens a market window in which clinically tested cannabis preparations have a regulatory advantage over flower-centered telemedicine models.
Significance for the German Medicinal Market
The German medicinal cannabis market stands at a turning point in spring 2026. Import volumes reached record heights in 2025, while political pressure on telemedicine and mail-order sales continues to grow. Vertanical’s market entry timing coincides with this consolidation phase, which is also described in a comprehensive market analysis by Prohibition Partners. For patients who are seeking initial guidance today through the Medicinal Cannabis Patient Guide 2026, an approved finished pharmaceutical could represent an additional therapeutic option in the medium term that does not require the controlled substance prescription pathway.
How statutory health insurance funds will handle reimbursement remains open. Unlike flower prescriptions, which must be approved case-by-case, Exilby would fall under regular reimbursement pathways for approved pain medications. Competition with established opioids and non-opioid analgesics will likely be decided through pricing, clinical practice guidelines, and health services research. The question of pharmaceutical quality assurance, addressed among other things in an analysis on microbial decontamination of medicinal cannabis in the EU, plays a fundamentally different role for a finished pharmaceutical than for unprocessed flowers.
Frequently Asked Questions
What exactly is VER-01?
VER-01 is a standardized full-spectrum extract from a specially developed Cannabis sativa strain of Munich-based company Vertanical. The preparation is administered as an oral liquid and was developed for the treatment of chronic back pain. The active ingredient contains, in addition to classical cannabinoids, cannabigerol as well as the terpenes beta-caryophyllene and alpha-bisabolol.
What does the FDA Breakthrough Therapy Designation mean?
The designation is not an approval but rather an accelerated consultation status from the US Food and Drug Administration. It commits the FDA to close guidance during ongoing development and expedited review once regulatory data are submitted. It is granted only when preliminary clinical data suggest substantial improvement over existing therapies.
When will the medication come to market in Germany?
Vertanical has announced that the European launch under the brand name Exilby should occur within weeks of the FDA Designation. Germany is designated as the first market, after which approval is expected to be extended to other EU member states via the mutual recognition procedure.
Does VER-01 replace prescription cannabis flowers?
No, the medication is an additional therapeutic option with a specific indication for chronic back pain. Cannabis flowers and extracts under the Medical Cannabis Act remain prescribable if the treating physician deems it appropriate. Exilby differs primarily in that it is a classically approved finished pharmaceutical with standardized dosing.
What is the difference from Epidiolex?
Epidiolex from Jazz Pharmaceuticals is an isolated cannabidiol active ingredient and was approved by the FDA in 2018 for rare epilepsy forms such as Dravet syndrome. VER-01, by contrast, is a full-spectrum extract with numerous cannabinoids and terpenes and targets chronic back pain, a significantly broader indication field. In the EU, Epidiolex has been approved since 2019 under the name Epidyolex, as was reported by Hanf-Magazin at the time.
Würdest du bei Rückenschmerzen ein Cannabis-Schmerzmittel wie VER-01 ausprobieren?
Sources: Business of Cannabis (05/29/2026), Vertanical press release on FDA Breakthrough Therapy Designation, Phase 3 publication in Nature Medicine (09/2025), FDA definition of Breakthrough Therapy Designation.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
